Why Avadel Pharmaceuticals Stock Is Crushing It Today
Shares of Avadel Pharmaceuticals (NASDAQ: AVDL) were skyrocketing 24.9% as of 11:19 a.m. EDT on Monday. The big jump came after the drugmaker announced positive results from a late-stage study evaluating the once-nightly sodium oxybate drug FT218 in treating excessive daytime sleepiness and cataplexy (a condition where a person collapses while remaining conscious) in patients with narcolepsy.
Avadel reported that all three doses of FT218 evaluated in the study met the three primary endpoints of improvement on the maintenance of wakefulness test (MWT), clinical global impression-improvement (CGI-I), and mean weekly cataplexy attacks.
Image source: Getty Images.
Source Fool.com